A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC)David R. Wise, Kwok‐Kin Wong, Cynthia A. Sirard et al.|Prostate Cancer and Prostatic Diseases|2024Cited by 9